BAY-390

BAY-390 is a selective, across species active and brain penetrating TRPA1 inhibitor. BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC 50 s of 16, 82, 63 and 35 nM, respectively. BAY-390 can be used for the research of inflammation In Vitro BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC 50 s of 16, 82, 63 and 35 nM, respectively. BAY-390 inhibits mTRPA1, gpTRPA1, dogTRPA1 and monkeyTRPA1 with IC 50 s of 73, 68, 81 and 19 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BAY-390 (30 and 90 mg/kg; p.o.; BID for 10 days) effects the neuropathic pain in vivo . BAY-390 reduces visceral pain in rat cyclophosphamide induced cystitis models . BAY-390 shows efficacy in inflammatory pain and neurogenic inflammation models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nrodent animals with neuropathic pain Dosage: 30 and 90 mg/kg Administration: Oral gavage; 30 and 90 mg/kg; twice daily for 10 days Result: Effectively reduced the neuropathic pain in rodent neuropathic pain model. Form:Oil IC50& Target:IC50: 16 nM (hTRPA1 FLIPR), 82 nM (hTRPA1 Ephys), 63 nM (rTRPA1 FLIPR), 35 nM (rDRG Ephys), 73 nM (mTRPA1), 68 nM (gpTRPA1), 81 nM (dogTRPA1)m, 19 nM (monkeyTRPA1)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet